Bill Burns

William M. Burns


Chairman of the Board of Directors

William “Bill” Burns is the Chairman of Molecular Partners. Bill Burns worked for Roche in various positions for 28 years culminating in the position as CEO of Roche Pharmaceuticals (2001-2009) and board seats at Roche (2010-2014), Genentech (2004-2014) and Chugai Pharmaceutical (2002-2014). He was non-executive Director (2011-2014) and Chairman (2014-2016) of BioTie Therapies Corp. Since 2010, he has been Non-Executive Director of Shire Pharmaceuticals, and from 2016 Senior Independent Director. He stepped down from the Shire Board in April 2018. Since 2011, Bill Burns has been a non-executive director of Vestergaard S.A. He became Chairman of Vestergaard in 2017. Bill Burns has been Vice-Chairman of Mesoblast since 2016. He is a Trustee and Governor of the Welcome Trust Ltd. and a Trustee of the Institute of Cancer Research, London. He is also a member of the Novo Holdings Advisory Group and a member of the Scientific Advisory Board Member of the Center for Integrated Oncology of the University of Cologne/Bonn. Bill Burns holds a bachelor’s degree in economics from the University of Strathclyde, Glasgow.